BRIEF-Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma

Reuters
31 Dec 2024
BRIEF-Adc <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma

Dec 30 (Reuters) - ADC Therapeutics SA ADCT.N:

  • ADC THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 3 CONFIRMATORY CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH RITUXIMAB IN 2L+ DIFFUSE LARGE B-CELL LYMPHOMA

Source text: ID:nPn4FzrXCa

Further company coverage: ADCT.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10